Routine prostate-specific antigen (PSA)-based screening for prostate cancer remains controversial, as the debate continues over the bank between potential benefits and potential harm. A new systematic review and meta-analysis has found that at best, prostate cancer screening using a PSA blood test leads to a small reduction in disease-specific mortality over 10 years, but it...